Search Resources (English): English, Women and Health Protection (WHP)

Results 41 - 50 of 63

Results

Remembering Ruth Cooperstock: women and pharmaceuticals 20 years later  
http://www.whp-apsf.ca/pdf/coopProceedingsEN.pdf
Presents the proceedings of a symposium that examined women and the pharmaceuticals industry. Includes presentations of the three panellists and a brief summary of each of the workshops. (See Details)
Published: 2006
Post-market surveillance of therapeutic drugs in Canada  
http://www.whp-apsf.ca/en/documents/adrBackground.html
Discusses the importance of an effective post-market surveillance system of therapeutic drugs. Lists problems with the current system, and argues that improvements will only occur when there is greater consumer involvement. (See Details)
Published: 2005
The inclusion of women in clinical trials: are we asking the right questions?  
http://www.whp-apsf.ca/pdf/clinicalTrialsEN.pdf
Addresses the issues evoked in considering the inclusion of women in clinical trials, highlighting especially where gender, even more than sex, is pertinent. (See Details)
Published: 2006
Illegal direct-to-consumer prescription drug advertising in Canada, 1999 to 2001: when drug companies skirt the law and the gove
Follows a campaign and complaint process regarding direct-to-consumer advertising of prescription drugs.
Published: 2002
Same tune, different lyrics: the Vioxx story  
http://www.cwhn.ca/node/39500
Illustrates the flaws in the Canadian drug approval and drug regulatory processes, using the current Vioxx scandal as example. (See Details)
Published: 2005
CanWest's Charter Challenge on prescription drug advertising: a citizen's guide  
http://www.whp-apsf.ca/pdf/charter_challenge_en.pdf
Discusses the background to this legal case, the implications for Canadians, and what you can do. (See Details)
Published: 2006
How safe are our medicines? Monitoring the risks of drugs after they are approved for marketing  
http://www.whp-apsf.ca/en/documents/how_safe.html
Discusses the drug approval process in Canada, post-approval drug surveillance, adverse drug reactions, and notification of those at risk of harm. Recommends measures to ensure drug safety for Canadian women and their families. (See Details)
Published: 2000
Pharmaceuticals manufacturing: what do we know about the occupational health and safety hazards for women working in the industry?   
http://www.whp-apsf.ca/pdf/Pharmaceutical%20Manufacturing-%20Health%20%20Safety%20_2_.pdf

Describes how pharmaceuticals are developed and produced, and what is known about the associated hazards. Includes an overview of health and safety laws in Canada and elsewhere, as well as some examples of relevant best practices. Concludes with a series of recommendations. Abridged version of “Occupational health and safety hazards in pharmaceuticals manufacturing: Past, present and future knowledge, policies and possibilities, particularly for women,” written by Dorothy Wigmore for Women and Health Protection.

 (See Details)
Published: March 2009
CanWest Charter Challenge on direct-to-consumer advertising of prescription drugs  
http://www.whp-apsf.ca/en/documents/charter.html

Discusses the Charter Challenge case of CanWest Mediaworks against the federal government on the issue of direct-to-consumer advertising  (DTCA). Reviews what the different parties are saying, and shows expert testimony on the specific harm to women of DTCA.

 (See Details)
Published: 2007
Pregnancy and mental health: a review of popular pregnancy information sources   
http://www.whp-apsf.ca/pdf/Pregnancy%20%20Mental%20Health.pdf

Examines the information available to the Canadian public through popular pregnancy information sources to assess gaps in information available and determine the extent, if any, of the difference between public information and medical literature on this topic.

 (See Details)
Published: March 2009